(1) The drug is recognized for treatment of the indication in at least one standard reference compendium;
(2) The drug is recommended for that particular type of cancer and found to be safe and effective in formal clinical studies, the results of which have been published in a peer reviewed professional medical journal published in either the United States or Great Britain.